Comparison of Renal Anastomosing Hemangiomas in End-Stage and Non-End-Stage Kidneys: A Meta-Analysis With a Report of 2 Cases.

Berker N., Bayram A., Tas S., Bakir B., Caliskan Y., Ozcan F., ...Daha Fazla

International journal of surgical pathology, cilt.25, sa.6, ss.488-496, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 6
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1177/1066896917706025
  • Dergi Adı: International journal of surgical pathology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.488-496
  • Anahtar Kelimeler: dialysis, end-stage renal disease (ESRD), meta-analysis, nephrectomy, renal anastomosing hemangioma, TUMOR-LIKE LESIONS, GENITOURINARY TRACT, CLINICOPATHOLOGICAL ANALYSIS, VASCULAR TUMORS, DISEASE, VARIANT, LOCATIONS, BIOPSY
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background. Renal anastomosing hemangioma (RAH) is a very rare distinct entity composed of anastomosing sinusoidal (spleen-like) capillary-sized vessels lined by flat or hobnail endothelial cells. Most of the published cases of RAH occurred in the setting of end-stage renal disease (ESRD). Methods. We present 2 cases of RAH in ESRD along with a literature review. We compared clinicopathologic features of RAHs in end-stage and non-end-stage kidneys. A meta-analysis was conducted with PubMed and a manual search through references of relevant publications. Individual patient data gathered from the literature were used in the analysis. Results. Our systematic review revealed 49 RAHs, including our 2 cases. Thirty-two (65.3%) cases were in ESRD, only 17 (34.7%) were in patients with non-ESRD. RAHs in ESRD were in younger patients, smaller in size, multifocal, and seen more with renal epithelial neoplasms when compared with RAHs in non-ESRD (P < .05). Extramedullary hematopoiesis was seen mostly in RAHs in ESRD kidneys (85% vs 41.7%) (P = .018). Follow-up data were available for 25 cases with a mean follow-up of 24.58 +/- 38.54 months. Recurrence, metastasis, or death have never been described related to RAH in any patients. Conclusions. In conclusion, RAHs are rare and mostly arise in kidneys with end-stage damage. RAHs in ESRD and non-ESRD differ in terms of clinicopathologic features.